---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-051815"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:49:43.148197+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics appoints two new directors, expanding board to five

## Summary
- Board increased from 3 to 5 members; Christopher W. Gerry (President & GC) and Phillip B. Donenberg appointed Feb 13, 2026.
- Gerry already serves as President and General Counsel of the company.
- Donenberg brings CFO and audit committee experience from Taysha, Tectonic, Jaguar Gene Therapy, and AveXis.
- Donenberg will receive non-employee director compensation per 2025 proxy statement.
- Each appointee entered standard indemnification agreement with the company.

## SEC filing metadata
- accession: 0001193125-26-051815
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526051815/0001193125-26-051815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526051815/d82134d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-051815
- JSON: https://secwatch.observer/filing/0001193125-26-051815.json
- Plain text: https://secwatch.observer/filing/0001193125-26-051815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.